XML 26 R20.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Stock-based Compensation
3 Months Ended
Apr. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation

11. Stock-based Compensation

The following table presents the classification of stock-based compensation for the periods indicated:

 

 

 

Three Months Ended April 30,

 

 

 

2024

 

 

2023

 

 

 

(in thousands)

 

Stock-based compensation:

 

 

 

 

 

 

Cost of revenue

 

$

607

 

 

$

941

 

Research and development

 

 

17,621

 

 

 

18,361

 

Selling, general and administrative

 

 

7,808

 

 

 

7,963

 

Total stock-based compensation

 

$

26,036

 

 

$

27,265

 

 

As of April 30, 2024, approximately $1.2 million of stock-based compensation expense was accrued in accrued and other current liabilities in the condensed consolidated balance sheets. Total unrecognized compensation cost related to unvested stock options at April 30, 2024 was $5.4 million and is expected to be recognized over a weighted-average period of 1.04 years. Total unrecognized compensation cost related to unvested restricted stock units at April 30, 2024 was approximately $181.3 million and is expected to be recognized over a weighted-average period of 2.43 years.

The following table sets forth the weighted-average assumptions used to estimate the fair value of employee stock purchase plan awards for the periods indicated:

 

 

 

Three Months Ended April 30,

 

 

 

2024

 

 

2023

 

Employee stock purchase plan awards:

 

 

 

 

 

 

Volatility

 

 

39

%

 

 

59

%

Risk-free interest rate

 

 

5.38

%

 

 

4.73

%

Expected term (years)

 

 

0.5

 

 

0.5

 

Dividend yield

 

 

0

%

 

 

0

%

 

The following table summarizes stock option activities for the period indicated:

 

 

 

Option Outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Intrinsic

 

 

Average

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-

 

Value Of

 

 

Remaining

 

 

Aggregate

 

 

 

 

 

 

Weighted-

 

 

Average

 

Options

 

 

Contractual

 

 

Intrinsic

 

 

 

 

 

 

Average

 

 

Grant-date

 

Exercised

 

 

Term

 

 

Value

 

 

 

Shares

 

 

Exercise Price

 

 

Fair Value

 

(in thousands)

 

 

(in years)

 

 

(in thousands)

 

Outstanding at January 31, 2024

 

 

373,318

 

 

$

46.39

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

(32,065

)

 

 

37.72

 

 

 

 

$

351

 

 

 

 

 

 

 

Expired

 

 

(62

)

 

 

11.16

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at April 30, 2024

 

 

341,191

 

 

 

47.21

 

 

 

 

 

 

 

 

3.43

 

 

$

1,956

 

Exercisable at April 30, 2024

 

 

304,129

 

 

$

48.61

 

 

 

 

 

 

 

 

3.05

 

 

$

1,409

 

 

The intrinsic value of options outstanding and exercisable is calculated based on the difference between the fair market value of the Company’s ordinary shares on the reporting date and the exercise price. The closing price of the Company’s ordinary shares on April 30, 2024 was $45.97, as reported by The Nasdaq Global Select Market. The intrinsic value of exercised options is calculated based on the difference between the fair market value of the Company’s ordinary shares on the exercise date and the exercise price.

The following table summarizes restricted stock unit activities for the period indicated:

 

 

 

 

 

 

Weighted-

 

 

 

 

 

 

Average

 

 

 

 

 

 

Grant-Date

 

 

 

Shares

 

 

Fair Value

 

Unvested at January 31, 2024

 

 

2,432,640

 

 

$

82.54

 

Granted

 

 

604,990

 

 

 

66.21

 

Vested

 

 

(335,348

)

 

 

73.44

 

Forfeited

 

 

(89,977

)

 

 

148.33

 

Unvested at April 30, 2024

 

 

2,612,305

 

 

$

77.66

 

 

As of April 30, 2024, the aggregate intrinsic value of unvested restricted stock units was $120.1 million.